CNBX Pharmaceuticals Inc. (CNBX) stock
CNBXOTCPharmaceutical PreparationsFiscal year ends August 31
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $197.79KP/E –Yield –
CNBX Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
CNBX Pharmaceuticals's operating cash flow for the twelve months ending May 31, 2026 was -$154.17K. For fiscal 2025 it was -$171.31K. The highest annual figure on record is $6.00K in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | -$171.31K | – |
| FY2024 | Aug 31, 2024 | -$244.27K | – |
| FY2023 | Aug 31, 2023 | -$112.52K | – |
| FY2022 | Aug 31, 2022 | -$1.68M | – |
| FY2021 | Aug 31, 2021 | -$2.49M | – |
| FY2020 | Aug 31, 2020 | -$2.77M | – |
| FY2019 | Aug 31, 2019 | -$3.09M | – |
| FY2018 | Aug 31, 2018 | -$1.97M | – |
| FY2017 | Aug 31, 2017 | -$863.57K | – |
| FY2016 | Aug 31, 2016 | -$120.10K | – |
| FY2015 | Aug 31, 2015 | -$179.06K | – |
| FY2014 | Aug 31, 2014 | -$195.42K | – |
| FY2013 | Aug 31, 2013 | -$27.25K | -554.2% |
| FY2010 | Aug 31, 2010 | $6.00K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | May 31, 2026 | -$47.67K | – |
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | -$30.55K | – |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | -$47.41K | – |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | -$28.55K | – |
| Q3 FY2025CQ2 2025 | May 31, 2025 | -$52.02K | -23219.6% |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | -$51.66K | – |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | -$39.08K | – |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | -$48.25K | -335.2% |
| Q3 FY2024CQ2 2024 | May 31, 2024 | $225 | – |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | -$124.40K | – |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | -$71.85K | – |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | $20.52K | – |
| Q3 FY2023CQ2 2023 | May 31, 2023 | -$18.59K | – |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | -$18.53K | – |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | -$95.92K | – |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | -$149.51K | – |
| Q3 FY2022CQ2 2022 | May 31, 2022 | -$375.36K | – |
| Q2 FY2022CQ1 2022 | Feb 28, 2022 | -$554.78K | – |
| Q1 FY2022CQ4 2021 | Nov 30, 2021 | -$599.55K | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$581.82K | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$616.12K | – |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | -$702.34K | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$592.64K | – |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -$713.96K | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -$575.68K | – |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -$723.63K | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$761.69K | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$868.67K | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$818.64K | – |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | -$739.34K | – |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | -$667.14K | – |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | -$621.50K | – |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -$465.62K | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -$434.60K | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -$452.97K | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$343.47K | – |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$205.44K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$167.70K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$146.96K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | -$69.38K | – |
See a number that looks wrong?